Equities

Renascience Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4889:TYO

Renascience Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,469.00
  • Today's Change14.00 / 0.96%
  • Shares traded186.50k
  • 1 Year change+17.61%
  • Beta0.7456
Data delayed at least 15 minutes, as of Feb 06 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Renascience Inc is mainly engaged in the development and sale of pharmaceuticals and medical devices. The company is engaged in the research and development of various modalities (pharmaceuticals, medical devices, artificial intelligence (AI) solutions) to solve problems in the medical field, in collaboration with physicians. The Company is engaged in the development of drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The Company is also engaged in the solve of other medical issues such as diseases of women and children, and COVID-19 infection.

  • Revenue in JPY (TTM)86.94m
  • Net income in JPY34.67m
  • Incorporated2000
  • Employees3.00
  • Location
    Renascience IncNo.401Kyodo Bldg., 2-3-6, Nihombashi Hon-choSENDAI-SHI 980-8575JapanJPN
  • Phone+81 227275070
  • Fax+81 362620973
  • Websitehttps://www.renascience.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CellSeed Inc120.30m-1.03bn10.91bn38.00--7.80--90.65-29.71-29.713.4737.830.05621.224.753,165,816.00-48.11-45.50-51.99-49.2952.7257.47-856.11-478.147.05--0.0949--1.65-6.87-1.57--6.39--
Stella Pharma Corp991.86m-180.01m11.16bn43.00--3.85--11.25-5.29-5.2929.1585.220.19580.10842.6723,066,440.00-3.55-16.41-3.74-18.1987.1587.03-18.15-176.1612.27-26.440.1917--256.62--81.56---21.34--
Wakamoto Pharmaceutical Co Ltd8.36bn72.14m11.88bn286.00164.041.0223.111.422.082.08240.90333.900.55491.603.2529,233,100.000.4788-0.06780.5454-0.078146.0748.650.8628-0.12462.60--0.0086--0.6595-6.53-40.86--21.87--
Immuno-Biological Laboratories Co., Ltd.1.01bn319.16m14.36bn58.0045.008.6742.5814.2134.2734.27108.54177.810.55980.94325.6817,429,220.0017.68-4.9620.73-5.7768.7762.7031.57-11.274.26--0.1028--18.7110.9533.40------
Kubota Pharmaceutical Holdings Co Ltd28.27m-768.36m14.43bn19.00--5.08--510.37-13.41-13.410.469324.610.0150.19622.841,487,632.00-40.79-41.04-44.63-44.8074.66---2,718.43-8,745.2118.25--0.0139---31.83--10.52------
TAIKO PHARMACEUTICAL CO LTD5.94bn853.00m14.63bn214.0017.011.7613.162.4616.9916.99118.31163.900.4751.432.9527,766,360.006.82--8.43--55.74--14.36--2.68--0.1105--2.81--124.87------
ReproCell Inc2.63bn-278.88m15.45bn99.00--1.78--5.87-2.94-2.9427.8591.620.28024.487.6226,588,680.00-2.97-4.09-3.18-4.4750.5043.75-10.59-13.6610.56--0.00--22.7419.94428.65---6.31--
CanBas Co Ltd (Parent)0.00-1.21bn17.17bn14.00--6.61-----62.53-62.530.00131.710.00----0.00-37.50-57.04-41.74-62.13-------4,587.85----0.00------4.27------
StemRIM Inc0.00-1.90bn18.55bn45.00--2.70-----30.56-30.560.00109.730.00----0.00-24.08-12.71-24.55-12.88-------167.3547.00--0.00------4.59---22.11--
Renascience Inc86.94m34.67m19.28bn3.00533.5211.79103.40221.742.732.736.84123.380.0478----28,981,330.001.90-8.972.00-9.3595.3184.4439.87-107.53----0.00---31.6613.00143.91------
Astena Holdings Co Ltd62.74bn2.19bn19.77bn1.42k8.870.71644.290.315154.2254.221,555.72671.410.89613.622.88--3.110.95876.261.7634.8530.403.471.050.9228--0.4519114.258.19-0.808186.601.9712.612.38
Ohki Healthcare Holdings Co Ltd359.41bn2.43bn20.52bn648.008.170.59868.600.0571178.43178.4326,346.692,435.832.269.834.34554,637,400.001.531.776.237.745.315.260.6770.69770.8306--0.268614.174.424.7419.412.2145.686.47
Fuso Pharmaceutical Industries Ltd62.05bn-3.99bn22.24bn1.34k--0.5908--0.3584-467.41-467.417,265.763,982.820.76883.152.5646,308,210.00-4.950.7682-9.871.2926.1926.94-6.431.050.786822.140.4359106.299.315.25-338.78--4.376.45
RaQualia Pharma Inc3.05bn-724.12m26.01bn85.00--4.05--8.53-30.73-30.73132.63247.060.31654.316.1535,872,500.00-7.520.1792-8.400.193174.5586.78-23.750.4534.48-13.690.33540.0063.4512.78-52.95--4.19--
Data as of Feb 06 2026. Currency figures normalised to Renascience Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.13%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 08 Jan 202616.80k0.13%
Data from 28 Jan 2026 - 28 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.